Home/LiberoThera/Toru Kanke, Ph.D.

TK

Toru Kanke, Ph.D.

Director

Therapeutic Areas

Oncology Immunology

LiberoThera Pipeline

Drug	Indication	Phase
Anti-CCR8 antibody	Cancer (likely solid tumors)	Preclinical

Leadership Team at LiberoThera

President & CEO

Makoto Ohori, Ph.D.

Sakae Asanuma, CFA, MBA

Shota Ozawa, Ph.D.

View full LiberoThera profile